JP2021507690A5 - - Google Patents

Claims (63)

A peptide comprising the amino acid sequence of SEQ ID NO: 27. The peptide according to claim 1, further comprising an N-terminal leader peptide having the sequence of SEQ ID NO: 7. The peptide according to claim 1, further comprising a linker peptide at the C-terminal. The peptide according to claim 3, wherein the linker peptide comprises the sequence of (GGGGS) n (where n is 1, 2, 3, or 4 in the formula). The peptide according to claim 4, wherein n is 1. The peptide according to claim 4, wherein n is 2. The peptide according to claim 4, wherein n is 3. The peptide according to claim 4, wherein n is 4. The peptide according to claim 1, further comprising an Fc peptide. The peptide according to claim 9, wherein the Fc peptide comprises the sequence of SEQ ID NO: 8 or SEQ ID NO: 15. The peptide according to claim 9, further comprising a leader peptide having the sequence of SEQ ID NO: 7 at the N-terminus. The peptide according to claim 9, wherein the Fc peptide is located at the C-terminal. The peptide according to claim 9, wherein the Fc peptide is located at the N-terminal. The peptide according to claim 1, further comprising the peptide of SEQ ID NO: 27 and a linker peptide linking the Fc peptide. The peptide according to claim 14, further comprising a leader peptide having the sequence of SEQ ID NO: 7 at the N-terminus. The peptide according to claim 14, wherein the linker peptide is (GGGGS) n (n is 1, 2, 3, or 4). The peptide according to claim 16, wherein n is 4. The peptide according to claim 14, wherein the Fc peptide comprises the sequence of SEQ ID NO: 8 or SEQ ID NO: 15. The peptide according to claim 14, wherein the Fc peptide is located at the C-terminal. The peptide according to claim 14, wherein the Fc peptide is located at the N-terminal. 14. The peptide of claim 14, comprising the peptide comprising the sequence of SEQ ID NO: 40. A pharmaceutical composition comprising the peptide according to claim 1. A pharmaceutical composition comprising the peptide according to claim 14. A pharmaceutical composition comprising the peptide according to claim 19. A pharmaceutical composition comprising the peptide according to claim 21. A peptide comprising the amino acid sequence of SEQ ID NO: 26. 16. The peptide of claim 16, further comprising an N-terminal leader peptide having the sequence of SEQ ID NO: 7. 26. The peptide of claim 26, further comprising a linker peptide at the C-terminus. 28. The peptide of claim 28, wherein the linker peptide comprises the sequence of (GGGGS) n (where n is 1, 2, 3, or 4 in the formula). 29. The peptide of claim 29, wherein n is 1. 29. The peptide of claim 29, wherein n is 2. 29. The peptide of claim 29, wherein n is 3. 29. The peptide of claim 29, wherein n is 4. 26. The peptide of claim 26, further comprising an Fc peptide. 34. The peptide of claim 34, wherein the Fc peptide comprises the sequence of SEQ ID NO: 8 or SEQ ID NO: 15. 34. The peptide of claim 34, further comprising a leader peptide having the sequence of SEQ ID NO: 7 at the N-terminus. The peptide according to claim 34, wherein the Fc peptide is at the C-terminus. The peptide according to claim 34, wherein the Fc peptide is at the N-terminus. 26. The peptide of claim 26, further comprising a peptide of SEQ ID NO: 26 and a linker peptide linking the Fc peptide. 39. The peptide of claim 39, further comprising a leader peptide having the sequence of SEQ ID NO: 7 at the N-terminus. 39. The peptide of claim 39, wherein the linker peptide is (GGGGS) n (n is 1, 2, 3, or 4). The peptide according to claim 41, wherein n is 4. 39. The peptide of claim 39, wherein the Fc peptide comprises the sequence of SEQ ID NO: 8 or SEQ ID NO: 15. The peptide according to claim 39, wherein the Fc peptide is located at the C-terminus. The peptide according to claim 39, wherein the Fc peptide is at the N-terminus. 39. The peptide of claim 39, comprising the peptide comprising the sequence of SEQ ID NO: 39. A pharmaceutical composition comprising the peptide according to claim 26. A pharmaceutical composition comprising the peptide of claim 39. A pharmaceutical composition comprising the peptide according to claim 43. A pharmaceutical composition comprising the peptide of claim 46. The peptide according to any one of claims 1 to 21 and 26 to 46 or any of claims 22 to 25 and 47 to 50, which is an in vitro method for activating T-regulatory cells. The method comprising contacting with the pharmaceutical composition according to claim 1. The pharmaceutical composition according to any one of claims 22-25 and 47-50 for use in a method of treating an inflammatory disorder in a subject, wherein the method comprises a subject in need thereof. , The pharmaceutical composition comprising the step of administering a therapeutically effective amount of the pharmaceutical composition. Inflammatory disorders include round alopecia, atopic dermatomyositis, herbivorous dermatomyositis, psoriasis, lupus, transplant-to-host disease (GVHD), inflammation, autoimmune disease, atopic disease, tumor-associated autoimmune disease, cartilage. Inflame, arthritis, rheumatoid arthritis, juvenile arthritis, juvenile rheumatoid arthritis, small arthritis juvenile rheumatoid arthritis, polyarticular juvenile rheumatoid arthritis, systemic juvenile rheumatoid arthritis, juvenile tonic dermatomyositis, juvenile enteritis Arthritis, juvenile reactive arthritis, juvenile Reiter syndrome, SEA syndrome (seronegative, tendon attachment, arthritis syndrome), juvenile dermatomyositis, juvenile psoriatic arthritis, juvenile arthritis, juvenile systemic Elythematosus, juvenile vasculitis, rheumatoid arthritis, rheumatoid arthritis, rheumatoid arthritis, rheumatoid arthritis, tonic dermatomyositis, enteritis arthritis, reactive arthritis, Reiter syndrome, SEA syndrome (seronegative, tendon attachment disease) , Arthritis syndrome), dermatomyositis, psoriatic arthritis, sclerosis, vasculitis, myitis, polymyositis, dermatomyositis, nodular polyarteritis, Wegener's granulomatosis, arthritis, rheumatic polymyositis, Sarcoidosis, sclerosis, primary bile sclerosis, sclerosing cholangitis, Schegren's syndrome, psoriasis vulgaris, drip psoriasis, reverse psoriasis, pustulous psoriasis, psoriatic erythema, dermatomyositis, atherosclerosis, Still disease, systemic erythematosus (SLE), severe myasthenia, inflammatory bowel disease (IBD), Crohn's disease, ulcerative arthritis, celiac disease, multiple sclerosis (MS), asthma, COPD, sinusitis, Reactive arthritis with polyps, eosinophil esophagitis, eosinophil bronchitis, Gillan Valley disease, type I diabetes, dermatomyositis (eg Graves disease), Addison's disease, Raynaud's phenomenon, autoimmune hepatitis, steroids Resistant chronic transplant piece-to-host disease, transplant rejection (eg kidney, lung, heart, skin, etc.), kidney injury, hepatitis C-induced vasculitis, loss of spontaneous pregnancy, alopecia, leukoplakia, focal segmental thread The pharmaceutical composition according to claim 52, which includes sphere sclerosis (FSGS), microvariant group, membranous nephropathy, ANCA-related glomerular nephropathy, membranous proliferative glomerulonephritis, IgA nephropathy, lupus nephritis and the like. thing. The pharmaceutical composition according to any one of claims 22 to 25 and 47 to 50 for use in a method of promoting or stimulating STAT5 phosphorylation in T-regulatory cells, wherein the method comprises the same. The pharmaceutical composition comprising the step of administering to a subject in need a therapeutically effective amount of the pharmaceutical composition. Use of the peptide according to any one of claims 1 to 47 or the pharmaceutical composition according to any one of claims 48 to 50 in the manufacture of a pharmaceutical product for the treatment of an inflammatory disorder. Inflammatory disorders include round alopecia, atopic dermatomyositis, herbivorous dermatomyositis, psoriasis, lupus, transplant-to-host disease (GVHD), inflammation, autoimmune disease, atopic disease, tumor-associated autoimmune disease, cartilage. Inflame, arthritis, rheumatoid arthritis, juvenile arthritis, juvenile rheumatoid arthritis, small arthritis juvenile rheumatoid arthritis, polyarticular juvenile rheumatoid arthritis, systemic juvenile rheumatoid arthritis, juvenile tonic dermatomyositis, juvenile enteritis Arthritis, juvenile reactive arthritis, juvenile Reiter syndrome, SEA syndrome (seronegative, tendon attachment, arthritis syndrome), juvenile dermatomyositis, juvenile psoriatic arthritis, juvenile arthritis, juvenile systemic Elythematosus, juvenile vasculitis, rheumatoid arthritis, rheumatoid arthritis, rheumatoid arthritis, rheumatoid arthritis, tonic dermatomyositis, enteritis arthritis, reactive arthritis, Reiter syndrome, SEA syndrome (seronegative, tendon attachment disease) , Arthritis syndrome), dermatomyositis, psoriatic arthritis, sclerosis, vasculitis, myitis, polymyositis, dermatomyositis, nodular polyarteritis, Wegener's granulomatosis, arthritis, rheumatic polymyositis, Sarcoidosis, sclerosis, primary bile sclerosis, sclerosing cholangitis, Schegren's syndrome, psoriasis vulgaris, drip psoriasis, reverse psoriasis, pustulous psoriasis, psoriatic erythema, dermatomyositis, atherosclerosis, Still disease, systemic erythematosus (SLE), severe myasthenia, inflammatory bowel disease (IBD), Crohn's disease, ulcerative arthritis, celiac disease, multiple sclerosis (MS), asthma, COPD, sinusitis, Reactive arthritis with polyps, eosinophil esophagitis, eosinophil bronchitis, Gillan Valley disease, type I diabetes, dermatomyositis (eg Graves disease), Addison's disease, Raynaud's phenomenon, autoimmune hepatitis, steroids Resistant chronic transplant piece-to-host disease, transplant rejection (eg kidney, lung, heart, skin, etc.), kidney injury, hepatitis C-induced vasculitis, loss of spontaneous pregnancy, alopecia, leukoplakia, focal segmental thread The use according to claim 55, which is globular sclerosis (FSGS), microvariant group, membranous nephropathy, ANCA-related glomerular nephropathy, membranous proliferative glomerulonephritis, IgA nephropathy, lupus nephritis, etc. A nucleic acid molecule encoding the peptide according to any one of claims 1 to 47. The vector containing the nucleic acid molecule according to claim 57. A plasmid comprising the nucleic acid molecule of claim 57. A cell comprising the nucleic acid molecule of claim 57. A cell comprising the plasmid according to claim 59. A cell comprising the vector according to claim 58. A cell comprising or expressing the peptide according to any one of claims 1 to 47 or the peptide described herein.